

103<sup>D</sup> CONGRESS  
1<sup>ST</sup> SESSION

# H. CON. RES. 22

Expressing the sense of the Congress with respect to contraception and infertility.

---

IN THE HOUSE OF REPRESENTATIVES

JANUARY 25, 1993

Mrs. SCHROEDER (for herself and Ms. SNOWE) submitted the following concurrent resolution; which was referred to the Committee on Energy and Commerce

---

## **CONCURRENT RESOLUTION**

Expressing the sense of the Congress with respect to contraception and infertility.

Whereas the incidence in the United States of both unintended pregnancy and abortion is substantial and unacceptable;

Whereas there is a significant incidence of infertility in the United States;

Whereas studies estimate that 31,800,000 women nationwide are at risk of unintended pregnancy, and that, for a variety of reasons, 13 percent of these women are not using any form of contraception;

Whereas there is a substantial need for the development of new contraceptive drugs and devices, but only 1 private

pharmaceutical company based in the United States is conducting research toward such development;

Whereas, if a variety of safe and effective options with respect to contraception are widely available, significant benefits for women and their families accrue, including a reduction in the number of low-birthweight births and a reduction in the number of premature births, leading to a reduced incidence of maternal and infant mortality;

Whereas it is estimated that 1 out of 6 couples in the United States is infertile or fails to conceive within 1 year of deciding to have a child;

Whereas the Centers for Disease Control estimates that 20 percent of cases of infertility in the United States are caused by sexually transmitted diseases;

Whereas cases of infertility resulting from sexually transmitted diseases are the most preventable of such cases;

Whereas, with respect to the problems of contraception and infertility, the obstacles to making an effective response to such problems are many and include a lack of consistent funding, the political controversy concerning abortion, the lengthy and complex procedures for the approval by the Food and Drug Administration of new drugs and devices, the costs of liability insurance for research and for the marketing of drugs and devices, and a shortage of scientists in the relevant fields; and

Whereas family planning is universally recognized as a human right: Now, therefore, be it

- 1 *Resolved by the House of Representatives (the Senate*
- 2 *concurring), That the Congress should—*

1           (1) establish a program of research for the de-  
2           velopment of new and improved methods of contra-  
3           ception and new and improved methods of diagnos-  
4           ing and treating infertility, including the establish-  
5           ment of research centers for such purposes;

6           (2) provide adequate long-term resources for  
7           the program to ensure that the program is among  
8           the principal Federal research priorities and that the  
9           United States is a world leader in research with re-  
10          spect to contraception and infertility;

11          (3) ensure that Federal programs with respect  
12          to the prevention, diagnosis, and treatment of sexu-  
13          ally transmitted diseases adequately respond to the  
14          role of such diseases in cases of infertility;

15          (4) ensure that the public is educated with re-  
16          spect to contraception and infertility, including edu-  
17          cation on new and improved drugs and devices;

18          (5) establish as Federal goals the development,  
19          by the year 2010, of—

20                  (A) improved barrier methods to protect  
21                  against unintended pregnancy and sexually  
22                  transmitted diseases;

23                  (B) new methods of contraception for use  
24                  by men;

1 (C) a vaccine-like drug for women that  
2 prevents unintended pregnancy for a significant  
3 period of time without disrupting the menstrual  
4 cycle or causing adverse metabolic or cardio-  
5 vascular effects; and

6 (D) new and improved techniques of diag-  
7 nosing and treating infertility;

8 (6) require the Secretary of Health and Human  
9 Services to take prompt action to reestablish the  
10 Ethical Advisory Board (terminated in 1980) in  
11 order to facilitate research with respect to infertility;

12 (7) review the policies and procedures of the  
13 Food and Drug Administration to determine the ex-  
14 tent to which the process of approving drugs and de-  
15 vices for use by the public, especially with respect to  
16 contraception and infertility, can be expedited with  
17 a reasonable degree of safety, including consider-  
18 ation of the role of conducting ongoing surveys and  
19 studies of the effects on the public of drugs and de-  
20 vices that have been so approved; and

21 (8) determine to what extent measures can be  
22 implemented by public or private entities to resolve  
23 liability issues regarding persons conducting re-  
24 search into, or marketing, drugs and devices with re-  
25 spect to contraception and infertility.

5

○